GleamWall
中文EN

PVCT PROVECTUS BIOPHARMACEUTICALS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 315545 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.5%
TTM net income YoY-14.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-30.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,575.3%
Net margin-1,615.8%
FCF margin—
EBITDA margin-1,574.8%

Returns

ROE—
ROA-637.5%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets1,003.6%
Debt / equity—
Current ratio0.08x
Interest coverage-991.90x

Cash quality & payout

Operating cash flow / net income0.61x
Accruals ratio-247.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$57,480$278,628$14,332
R&D expense$240,320$131,130$333,334$268,428$345,861$880,835$402,704$556,678
SG&A expense$971,045$807,548$914,569$852,061$929,746$977,373$973,865$1.79M
Operating income-$1.21M-$938,678-$1.25M-$1.12M-$1.28M-$1.80M-$1.10M-$2.33M
Interest expense$62,345$50,319$53,046-$157,698$48,022$51,353$63,661—
Net income-$1.27M-$982,566-$1.29M-$1.17M-$1.31M-$1.81M-$1.14M-$2.37M
EBITDA-$1.21M-$938,212-$1.25M-$1.12M-$1.28M-$1.80M-$1.10M-$2.33M
EPS (basic)0.000.000.00—0.000.000.00—
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)420.28M420.28M420.28M—420.28M420.28M420.28M—
Banking
Net interest income———-$47,323-$48,022-$51,353-$63,661-$62,322
Balance sheet
Cash & equivalents$180,733$1.16M$223,883$251,291$72,479$385,929$390,435$307,442
Current assets$375,197$1.37M$460,385$567,874$277,988$568,320$649,469$976,772
PP&E, net$1,603$2,068$2,534$3,000$3,465$3,931$4,396$4,863
Total assets$467,087$1.47M$577,580$697,502$419,904$722,384$666,257$1.01M
Current liabilities$7.11M$7.71M$7.24M$6.90M$6.47M$6.49M$5.74M$6.98M
Total liabilities$7.15M$7.76M$7.31M$7.00M$6.59M$6.60M$5.74M$6.98M
Shareholders' equity-$6.66M-$6.28M-$6.72M-$6.30M-$6.15M-$5.87M-$5.10M-$5.96M
Shares outstanding420.28M420.28M420.28M420.28M420.28M420.28M—420.28M
Cash flow statement
Operating cash flow-$859,595-$358,249-$357,565-$869,553-$839,867-$523,127-$1.09M-$912,008
Financing cash flow-$116,755$1.29M$329,872$1.05M$495,903$469,759$1.07M$788,419
Depreciation & amortization$465$466$466$465$466$465$467$466
Stock-based compensation$309,306$305,944$306,051$287,601$312,775$322,070$315,100$331,371

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.